UK-based healthcare company GlaxoSmithKline (GSK) has announced an investment of €17.5m ($23.5m) in a French venture firm to develop new drugs that have the potential to target rare diseases in Europe.
The Kurma Biofund II fund is led by Paris-based venture capital firm Kurma Life Science Partners (KLS) and is supported by other investors namely, CDC Entreprises, Idinvest Partners and New Enterprise Associates.